Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Rx Importation Unsustainable Because Of Supply/Demand Imbalance – HDMA

  • News

Executive Summary

Increased demand for a small amount of Canadian pharmaceuticals would make a legalized importation system unsustainable, drug distributors told the HHS importation task force

You may also be interested in...



Canadian Rx Imports Would Be 10% Of U.S. Market, Caremark CEO Says

Prescription drugs from Canada would make up 10% of the U.S. drug market if importation were legalized, Caremark CEO Mac Crawford said Oct. 25

Canadian Rx Imports Would Be 10% Of U.S. Market, Caremark CEO Says

Prescription drugs from Canada would make up 10% of the U.S. drug market if importation were legalized, Caremark CEO Mac Crawford said Oct. 25

CVS Endorses Imports; Infrastructure Already In Place, CEO Says

Much of the infrastructure for importing drugs is already in place, CVS CEO Thomas Ryan said May 5 at a meeting of the HHS importation task force

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS043735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By